Source: Annual Congress 2009 - Pathogenesis of lung cancer
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. H. Aly, W. A. Elrefaey, E. H. Alqurashi (Makkah, Saudi Arabia). The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule. Eur Respir J 2009; 34: Suppl. 53, 4207

Member's Comments

No comment yet.

Related content which might interest you: Is caveolin-1 lost as a tumor suppressor gene in lung carcinoma? Source: Annual Congress 2004 - Lung development and cancer Year: 2004 The role of tumor size in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 93s Year: 2006 Tumoural tissue specific promoter hypermethylation of distinct tumour suppressor genes in a case with nonsmall cell lung carcinoma: a case report Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer Year: 2009 Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Evaluating the role of muc4 expression in the differential diagnosis of mesothelioma and adenocarcinoma of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 81s Year: 2006 Recognition of aberrant promoter methylation for early diagnosis of lung cancer patients Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 The role of TTF-1 in differentiation of primary and metastatic adenocarcinomas of the lung Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Prognostic value of promoter hypermethylation of tumor suppressor genes in malignant pleural fluid Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011 HER-2/neu overexpression in patients with lung carcinoma Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Does expression of betatubulin 3 correlate between primary non small cells lung cancer tumor and metastases? Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Correlation of P53 and CerbB-2 expression in the diagnostic biopsies and the corresponding resected tumors in non small cell lung caner Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004 Inhibition of tumor growth and metastatic lung tumors in mice by adenovirus-mediated interferon-β gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011